Compare IQIYI Inc - ADR (IQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs TransMedics Group Inc — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.8× IQIYI Inc - ADR's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 4,964,108). Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and TransMedics Group Inc for 24 Days on average.
| IQ | TMDX | |
|---|---|---|
Market Cap | $974.67M | $2.74B |
Volume | 4,964,108 | 949,331 |
Sector | Media | Health |
52-Week High | $2.35 | $150.42 |
52-Week Low | $0.86 | $61.99 |
Typical Hold Time | 55 Days | 24 Days |
Enterprise Value | $2.47B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.01, down 0.49% with bearish technical signals. The company reported Q2 2026 revenue of RMB 6.3 billion with a narrowed operating loss, while full-year 2025 showed revenue decline to $27.29B and net loss of $206M. Analyst consensus is mixed with 50% buy ratings amid ongoing business transformation toward AI-driven content production.
The outlook remains challenging with streaming revenue pressure, though AI initiatives show promise. Key risks include competitive threats and execution uncertainty. Wall Street maintains cautious optimism with 11 buy ratings but requires evidence of sustainable profitability turnaround.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
